According to Parexel, the new depot in Singapore and ancillary warehouse in Russia will support its clients in more effectively managing their global clinical trial supply requirements. The
According to Novartis, 82% of the patients achieved disease control and 74% of them achieved tumour reduction at a median follow-up of 9.6 months. The primary endpoint, which
The global, open label, multicentre trial, the Bosutinib Efficacy and safety in chronic myeloid LeukemiA (BELA) study, enrolled 502 adult patients who were randomised to receive either bosutinib
As president of the company, Lau will oversee strategic planning and business development, partnership management and organisation development. Prior to joining China Biologic, Lau served from 2002 to
Under the terms of the agreement, Champions will use its Tumorgraft platform to test the effectiveness of Teva‘s compound in various cancer indications to assist in further clinical
Bristol-Myers Squibb and Otsuka Pharma said that the study results were consistent with 12-month data in which Sprycel demonstrated higher and faster rates of complete cytogenetic response (CCyR)and
McKesson claims the CytoCare is the only proven automation solution for compounding hazardous IVs used for chemotherapy and monoclonal antibody therapy. The new technology will enable the 800-bed
As per the agreement, Ascenta will conduct its first Phase I trial of AT-406 in adults with AML in combination with the standard AML induction regimen, and expects
Sangart has entered into this CRADA with the US Naval Medical Research Center and the Uniformed Services University of Health Sciences. The agreement will allow the US Navy
Both compounds were discovered and developed by Gruenenthal and represent novel molecules with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.